What the Evidence Does NOT Show Because the marketing around these compounds is expansive, it is worth stating explicitly what the published record does not establish: It does not show that cagrilintide is superior, equal, or inferior to tirzepatide no head-to-head trial exists, so any ranking is cross-trial inference
Severe hepatic impairment : Canagliflozin is not recommended in patients with severe hepatic impairment due to limited clinical experience
The Weight Loss and Health Beenfits of GLP-1 Therapy Beyond stabilizing blood sugar, GLP-1 receptor agonists offer a wide range of systemic health advantages
The testosterone levels of the men in the study were, however, all in a range that would unlikely have an impact on their fertility
2.0%, p = 0.585), no significant difference was observed